« Back
Home /
Ibrutinib

Ibrutinib

Item no.	TMO-T1835-500mg
Manufacturer	TargetMol
CASRN	936563-96-1
Amount	500 mg
Quantity options	1000 mg 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mL 200 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Reagents & Chemicals Molecules By Organ Bladder Cancer
Type	Molecules
Specific against	other
Citations	1. Burger JA1, Buggy JJ. Leuk Lymphoma. 2013 Nov;54(11):2385-91.
Smiles	NC1=C2C(N(N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@H]5CN(C(C=C)=O)CCC5)=NC=N1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	PCI-32765
Shipping Condition	Cool pack
Available
Manufacturer - Targets	Src\|\|\|Ligands for Target Protein for PROTAC\|\|\|BTK\|\|\|Tyrosine Kinases
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	440.5
Description	Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
Pathways	PROTAC\|\|\|Tyrosine Kinase/Adaptors\|\|\|Angiogenesis
Bioactivity	PCI-32765(Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
Receptor	BLK; Bmx; BTK; FGR; CSK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T1835-500mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 500 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question